-
Tacrine hydrochloride hydrate: Applied Assay Workflows
2026-08-19
Build reproducible AChE/BuChE inhibition, cholinergic signaling, and neuroprotection workflows with Tacrine hydrochloride hydrate. This guide combines concentration planning, metabolism-aware assay design, and troubleshooting for Alzheimer’s disease research and neurodegenerative disease models.
-
Amyloid β-Peptide (1-42): Assay Workflows
2026-08-18
Build reproducible neuronal toxicity, microglial clearance, and ion-channel experiments with a defined Aβ42 peptide challenge. This workflow translates evidence on ATP–P2Y2 signaling into practical controls, timing choices, and troubleshooting strategies for Alzheimer’s disease research.
-
Sodium salicylate in PDAC NF-κB assays
2026-08-18
Sodium salicylate provides a soluble NF-κB inhibition arm for separating inflammatory signaling from the physical effects of pancreatic tumor stroma. This workflow shows how to integrate it into PDAC cell, co-culture, and nanomedicine assays while controlling solubility, timing, pH, and interpretation.
-
NLRP10, Keratinocyte Survival, and AD Barrier Function
2026-08-17
The reference study identifies NLRP10 as an epidermal homeostasis regulator that supports keratinocyte survival, p63-dependent differentiation, and barrier integrity. Its use of human skin-equivalent models connects AD-associated genetics with distinct cell-death and differentiation mechanisms, while also defining important limits for therapeutic translation.
-
Docosahexaenoic Acid: Mechanisms for Better Assays
2026-08-17
Explore how Docosahexaenoic Acid (DHA) shapes membrane signaling, inflammation, neuronal survival, and assay design. This article also contrasts DHA evidence with a recent arachidonic acid vaccine-immunity study to clarify what researchers can—and cannot—translate across omega-3 and omega-6 biology.
-
Ferroptosis Signature and Atorvastatin in HCC
2026-08-16
Wang et al. combine transcriptomic survival modeling with Connectivity Map screening to identify a four-gene ferroptosis-related prognostic signature and nominate Atorvastatin for hepatocellular carcinoma research. In vitro and in vivo experiments reported that Atorvastatin inhibited HCC growth and migration while inducing ferroptosis, providing a preclinical rationale for further validation rather than clinical proof.
-
Catalpol N1352: Reliable Cell Assay Workflows
2026-08-15
Learn how Catalpol (SKU N1352) can improve the interpretation and reproducibility of cell viability, proliferation, and cytotoxicity experiments. This scenario-based guide connects concentration planning, solvent control, pathway biology, orthogonal validation, and product selection to published neuroinflammation evidence.
-
17-AAG (Tanespimycin): Chaperones and Cell Fate
2026-08-14
17-AAG (Tanespimycin) offers a translational framework for studying HSP90-dependent oncogenic signaling, apoptosis, and the broader question of how regulated cell death shapes selective protein release.
-
MCT4 Loss Drives Ferroptosis in Bladder Cancer
2026-08-14
Dong, Zheng, and Jiang identify lactate/proton monocarboxylate transporter 4 (MCT4) as a metabolic regulator of ferroptosis in human bladder cancer 5637 cells. Their data connect MCT4 depletion with oxidative damage, AMPK/ACC pathway changes, reduced autophagy, and greater sensitivity to ferroptosis-inducing treatments, supporting MCT4 as a candidate vulnerability in bladder cancer.
-
Baicalin methyl ester: Assay Design Guide
2026-08-13
Learn how Baicalin methyl ester (SKU N2884) can support better-controlled MODE-K cell viability, inflammatory, and intestinal barrier experiments. This scenario-based guide connects published P65/TNF-α/MLCK/ZO-1 findings with practical dosing, solvent, control, and interpretation strategies.
-
SB 202190: A Causal Probe for Cancer Assays
2026-08-13
SB 202190 is a selective p38 MAP kinase inhibitor for testing whether p38-dependent signaling contributes to inflammation, apoptosis, and colorectal cancer phenotypes. This article translates recent β-sitosterol–TBX20 findings into a rigorous assay strategy rather than repeating a conventional product overview.
-
EZ Cap™ Cas9 mRNA (5-moUTP) for Reliable Assays
2026-08-12
Cell viability and cytotoxicity assays can be confounded by delivery stress, innate immune activation, and inconsistent mRNA handling. This scenario-based guide explains how EZ Cap™ Cas9 mRNA (5-moUTP), SKU R1015, supports more controlled CRISPR-Cas9 genome editing workflows through its Cap1 structure, 5-moUTP modification, poly(A) tail, and defined formulation.
-
Measuring Drug Response Beyond Relative Viability
2026-08-12
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent drug responses. This framework helps researchers design cancer assays that resolve response magnitude, mechanism, and timing rather than treating every viability decrease as apoptosis.
-
(R,S)-Anatabine: Aβ Research Mechanism
2026-08-11
(R,S)-Anatabine is a minor Solanaceae alkaloid used to investigate amyloid-beta production and neuroinflammation. Product information describes dose-dependent reduction of Aβ1-40 and Aβ1-42 through reduced APP β-cleavage, lower BACE-1 expression, and suppressed NF-κB activation.
-
Calpain Inhibitor II, ALLM: Mapping Protease Fate
2026-08-11
Calpain Inhibitor II, ALLM enables cleavage-centered studies of calpain and cathepsin biology. This article connects the FAISL–calpain 2–FAK axis in triple-negative breast cancer with practical assay decisions in leukemia, lymphoma, and protease research.